Barbara Sennino
Head Senior VP, Early Development 3T Biosciences
Seminars
Wednesday 26th August 2026
Panel Discussion: Reflecting on Computational & AI Drug Design Approaches for Biologics Therapeutics
9:30 am
To kick off, this industry leaders panel will discuss the computational x AI x biologics industry collaborations and advancements shaping the space over the last year, key challenges to be overcome, and identify the biggest opportunities based on industry trends.
- Taking a strategic SWOT analysis approach, what are the strengths, weaknesses, opportunities and threats to AI/ML-derived biologics?
- What advancements in AI/ML and computational tool convergence should we be most excited about when it comes to biologics design and optimization?
- What are the technical or scientific bottlenecks that are slowing down computational x AI x biologics design and optimization?
- Reflecting on the last year, what have been some of the most exciting industry collaborations that have given momentum to the computational x AI x biologics space?
- What can we learn from these collaborations in terms of where the space is heading?
Thursday 27th August 2026
Harnessing AI for Smarter Antigen Selection & More Effective TCE Design
1:30 pm
- Using ML to integrate diverse datasets and map antigen prevalence across cancer and normal tissues
- Applying the 3T-TRACE platform to assess TCR and TCR-mimetic specificity and off-target cross-reactivity
- Engineering highly specific and safe T-cell engagers against shared targets for effective treatment of solid tumors
